KRAS and neoplasm: Importantly, in vivo tumour growth 22 days post-implant was significantly greater in tumours derived from mutant KRAS -PDHK4 stable clones 1 and 7 than in the empty vector clone (Figure 7a and Supplementary Figure S5E).